Balyasny Asset Management
SLNO

Balyasny Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Balyasny Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$3.57M – 3303
2025
Q1 		$3.57M Hold
50,000
– – 0.01% 1412
2024
Q4 		$2.25M Buy
+50,000
New +$2.59M ﹤0.01% 1630

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Balyasny Asset Management's SLNO Position: Q1 2026 in Review

Balyasny Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 227,751 shares — an estimated $10.5M sold.

Balyasny Asset Management first reported a position in SLNO in Q3 2023 and held it in 9 quarters. The position peaked at $44.7M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Balyasny Asset Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 227,751 Soleno Therapeutics shares in Q1 2026, an estimated $10.5M.
  • Balyasny Asset Management first reported a position in Soleno Therapeutics in Q3 2023 and held it in 9 quarters.
  • Balyasny Asset Management's Soleno Therapeutics position peaked at $44.7M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.